Key Drivers
- Strong Margins
- Weak Cash Conversion
- Rich Valuation
AIAI Summary
WST has shifted from a simple defensive med-tech compounder to a premium-valued growth story now dependent on sustaining biologics/HVP/GLP-1 momentum, so the key takeaway is to watch whether improving margins and cash conversion can hold through the CEO transition—otherwise the current multiple is vulnerable to a quick de-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Weak Cash Conversion
- •Rich Valuation
West Pharmaceutical combines strong margins, solid liquidity, and low leverage with weaker cash conversion and a demanding valuation, so the stock looks high quality but priced for perfection.
Price Behavior
Key Price Behavior Insights:
- •Rebound Holding
- •Mid-350s Cap
- •Range-Bound Trade
Over the last month, WST has rebounded from a late-July low near $327.99 into the $340s but remains capped by $354-$358 resistance, leaving the setup neutral to mildly positive unless it can reclaim that band.
Rebounded from a late-July trough near $327.99, but rallies have repeatedly stalled in the mid-$350s
Sentiment & News
Key News Insights:
- •HVP Momentum
- •Raised Guidance
- •Premium Valuation
West Pharmaceutical beat Q2 expectations and raised 2026 guidance on strong HVP, biologics, and GLP-1 demand, but its premium valuation and execution risks limit near-term upside.
The strong earnings reset and outlook support WST's trend higher, but the stock may remain sensitive to any slowdown given its elevated valuation
Similar Companies in Healthcare
Other companies in the same sector with AI ratings